+

AR036081A1 - Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos - Google Patents

Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos

Info

Publication number
AR036081A1
AR036081A1 ARP020102090A ARP020102090A AR036081A1 AR 036081 A1 AR036081 A1 AR 036081A1 AR P020102090 A ARP020102090 A AR P020102090A AR P020102090 A ARP020102090 A AR P020102090A AR 036081 A1 AR036081 A1 AR 036081A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
heterocycloalkyl
cycloalkyl
Prior art date
Application number
ARP020102090A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR036081A1 publication Critical patent/AR036081A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen y reivindican compuestos inhibidores del virus ARN de fórmula (1) en la cual: R1 es hidrógeno, halógeno, alquilo C1-4, -OR11, -SR11, -NR10R11, arilo, -C(O)OH, -C(O)NHR11, ciano o nitro; R2 es hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-6, heterocicloalquilo, arilo, heteroarilo, nitro, ciano, halógeno, -C(O)OR9, -C(O)R9, -C(O)NR9R10, -OR9, -SR9, -S(O)R12, -S(O)2R9, -NR9R10, -OH protegido, -N(R10)C(O)R9, -OC(O)NR9R10, -N(R10)C(O)NR9R10, -P(O)(OR9)2, -SO2NR9R10, ó -N(R10)SO2R9, estando dichos alquilo C1-8, alquenilo C2-8 o alquinilo C2-8, sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre halógeno, -OH, -SH, -NH2, -O-alquilo C1-4, -S-alquilo C1-4, -NR10R11, ciano, nitro, -CO2R10, -C(O)O-alquilo C1-4, -CONR10R11, -CONH2, arilo y heteroarilo, y estando dichos cicloalquilo, heterocicloalquilo, arilo o heteroarilo sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre alquilo C1-6, haloalquilo C1-6, halógeno, -OH, -SH, -NH2, -O-alquilo C1-4, -S-alquilo C1-4, -N(alquilo C1-4)(alquilo C1-4), -NH(alquilo C1-4), ciano, nitro, -CO2H, -C(O)O-alquilo C1-4, -CON(alquilo C1-4)(alquilo C1-4), -CONH(alquilo C1-4) y -CONH2; R3 es hidrógeno, halógeno, ciano, alquilo C1-6, -OH ó -CO2H; cada uno de R4, R5 y R6 se seleccionan independientemente entre el grupo compuesto por hidrógeno, halógeno, ciano, alquilo C1-6, -OH y -O-alquilo C1-4; R7 es hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-6, heterocicloalquilo, arilo, heteroarilo, nitro, ciano, halógeno, -C(O)OR9, -C(O)R9, -C(O)NR9R10, -OR9, -SR9, -S(O)R12, -S(O)2R12, -NR9R10, -OH protegido, -N(R12)C(O)R9, -OC(O)NR9R10, -N(R12)C(O)NR9R10, -P(O)(OR9)2, -SO2NR9R10, ó -N(R10)SO2R12, estando dichos alquilo C1-8, alquenilo C2-8 o alquinilo C2-8, sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre halógeno, -OH, -SH, -NH2, -O-alquilo C1-4, -S-alquilo C1-4, -NR10R11, ciano, nitro, -CO2H, -C(O)O-alquilo C1-4, -CONR10R11, -CONH2, arilo, heteroarilo, heterocicloalquilo, -C(O)arilo, -C(O)heterocicloalquilo y -C(O)heteroarilo, estando dicho arilo, heteroarilo, heterocicloalquilo, -C(O)arilo, -C(O)heterocicloalquilo ó -C(O)heteroarilo sin sustituir o sustituido con uno o más sustituyentes seleccionados independientemente entre alquilo C1-4, haloalquilo C1-4, halógeno, -OH,-SH, -NH2, -O-alquilo C1-4, -S-alquilo C1-4, -N(alquilo C1-4)(alquilo C1-4), -NH(alquilo C1-4), ciano y nitro; y estando dichos cicloalquilo, heterocicloalquilo, arilo o heteroarilo sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre alquilo C1-6, haloalquilo C1-6, halógeno, -OH, -SH, -NH2, -O-alquilo C1-4, -S-alquilo C1-4, -N(alquilo C1-4)(alquilo C1-4), -NH(alquilo C1-4), ciano, nitro, -CO2H, -C(O)O-alquilo C1-4, -CON(alquilo C1-4)(alquilo C1-4), -CONH(alquilo C1-4), y -CONH2; R8 es hidrógeno, halógeno, hidroxi o alquilo C1-4; ó R1 y R2 ó R5 y R6 ó R6 y R7 ó R7 y R8 tomados conjuntamente son alquilendioxi; W es hidrógeno, -C(O)OR11, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-6, -(alquil C1-6)-(cicloalquilo C3-6), -(alquenil C2-6)-(cicloalquilo C3-6), -(alquinil C2-6)-(cicloalquilo C3-6), -(alquil C1-6)-heterocicloalquilo, -(alquenil C2-6)-heterocicloalquilo, -(alquinil C2-6)-heterocicloalquilo, -(alquil C1-6)-arilo, (alquenil C2-6)-arilo, -(alquinil C2-6)-arilo, -(alquil C1-6)-heteroarilo, -(alquenil C2-6)-heteroarilo ó -(alquinil C2-6)-heteroarilo, estando dichos alquilo C1-10, alquenilo C2-10 y alquinilo C2-10 sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre halógeno, ciano, -OH, -O-alquilo C1-4, -SH, -S-alquilo C1-4, -S(O)(alquilo C1-4), -S(O)2H y -S(O)2(alquilo C1-4); dicho cicloalquilo C3-6 está sin sustituir o sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, ciano, alquilo C1-4, -OH, -O-alquilo C1-4, -SH, -S-alquilo C1-4, -S(O)(alquilo C1-4), -S(O)2H y -S(O)2(alquilo C1-4), y estando los restos cicloalquilo, heterocicloalquilo, arilo o heteroarilo de dichos -(alquil C1-6)-(cicloalquilo C3-6), -(alquenil C2-6)-(cicloalquilo C3-6), -(alquinil C2-6)-(cicloalquilo C3-6), -(alquil C1-6)-heterocicloalquilo, -(alquenil C2-6)-heterocicloalquilo, -(alquinil C2-6)-heterocicloalquilo, -(alquil C1-6)-arilo, (alquenil C2-6)-arilo, -(alquinil C2-6)-arilo, -(alquil C1-6)-heteroarilo, -(alquenil C2-6)-heteroarilo ó -(alquinil C2-6)-heteroarilo, sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre alquilo C1-6, haloalquilo C1-6, halógeno, ciano, nitro, -OH, -NH2, -O-alquilo C1-4, -N(alquilo C1-4)(alquilo C1-4) y -NH(alquilo C1-4); X es O ó S; Y es -OH ó -SH; Z es hidrógeno o alquilo C1-4; en la que R9 se selecciona independientemente entre el grupo compuesto por hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, heterocicloalquilo, arilo, heteroarilo, -alquil C1-6-cicloalquilo C3-8, -alquil C1-6-heterocicloalquilo, -(alquil C1-6)-arilo, y -(alquil C1-6)-heteroarilo, -(alquenil C2-6)-(cicloalquilo C3-6), -(alquenil C2-6)-heterocicloalquilo, -(alquenil C2-6)-arilo, -(alquenil C2-6)-heteroarilo, -(alquinil C2-6)-(cicloalquilo C3-6), -(alquinil C2-6)-heterocicloalquilo, -(alquinil C2-6)-arilo, y -(alquinil C2-6)-heteroarilo, estando dichos alquilo C1-8, alquenilo C2-8 ó alquinilo C2-8, sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre halógeno, -OR11, -NR10R11, ciano, nitro, -CO2R11, -CONR10R11,-NR10CONR10R11, -OCONR10R11, -SO2NR10 y -COR11, y estando dichos cicloalquilo, heterocicloalquilo, arilo o heteroarilo (incluyendo los restos cicloalquilo, heterocicloalquilo, arilo o heteroarilo de dichos -alquil C1-6-cicloalquilo C3-8, -alquil C1-6-heterocicloalquilo, -(alquil C1-6)-arilo, ó -(alquil C1-6)-heteroarilo sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre alquilo C1-4, haloalquilo C1-4, halógeno, -OR11, -NR10R11, ciano, nitro, -CO2R11, -CONR10R11, -NR10CONR10R11, -OCONR10R11, -SO2NR10R11 y -COR11; cada R10 se selecciona independientemente entre hidrógeno y alquilo C1-6; cada R11 se selecciona independientemente entre el grupo compuesto por hidrógeno, alquilo C1-6, cicloalquilo C3-6, heterocicloalquilo, arilo, heteroarilo, -alquil C1-4-cicloalquilo C3-8, -alquil C1-4-heterocicloalquilo, -alquil C1-4-arilo ó -alquil C1-4-heteroarilo; estando dichos cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo o heteroarilalquilo sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre alquilo C1-6, haloalquilo C1-6, halógeno, -O-alquilo C1-6, -O-haloalquilo C1-6, ciano, -N(alquilo C1-6)(alquilo C1-6), -NH(alquilo C1-6), -NH2, -CO2-alquilo C1-6, -CO2H, -CON(alquilo C1-6)(alquilo C1-6), -CONH(alquilo C1-6) y -CONH2; o cuando está presente en cualquiera de NR9R10 ó NR10R11, cada uno de R9 y R10 o cada uno de R10 y R11, independientemente, tomados junto con el nitrógeno al que están unidos representan un anillo de 3-6 miembros que contiene opcionalmente otro heteroátomo seleccionado entre oxígeno y nitrógeno, estando dicho anillo de 3-6 miembros sin sustituir o sustituido con uno o más sustituyentes seleccionados independientemente entre hidrógeno, alquilo C1-6, halógeno, ciano, -O-alquilo C1-6, -OH, -N(alquilo C1-6)(alquilo C1-6), -NH(alquilo C1-6), -NH2, -CO2H, -C(O)O-alquilo C1-6, -C(O)alquilo C1-6, -CON(alquilo C1-6)(alquilo C1-6), -CONH(alquilo C1-6), -CONH2, cicloalquilo C3-6, heterocicloalquilo, arilo, heteroarilo, cicloalquil C1-6-alquilo C1-6, heterocicloalquil-alquilo C1-6, aril-alquilo C1-6, y heteroaril-alquilo C1-6, y estando dichos cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo ó heteroarilalquilo sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre alquilo C1-6, haloalquilo C1-6, halógeno, -O-alquilo C1-6, -O-haloalquilo C1-6, ciano, -N(alquilo C1-6)(alquilo C1-6), -NH(alquilo C1-6), -NH2, -CO2-alquilo C1-6, -CO2H, -CON(alquilo C1-6)(alquilo C1-6), -CONH(alquilo C1-6) y -CONH2; cada R12 se selecciona independientemente entre el grupo compuesto por hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, heterocicloalquilo, arilo, heteroarilo, -alquil C1-6-cicloalquilo C3-8, -alquil C1-6-heterocicloalquilo, -alquil C1-6-arilo y -alquil C1-6-heteroarilo, -alquenil C2-6-cicloalquilo C3-8, -alquenil C2-6-heterocicloalquilo, -alquenil C2-6-arilo, -alquenil C2-6-heteroarilo, -alquinil C2-6-cicloalquilo C3-8, alquinil C2-6-heterocicloalquilo, -alquinil C2-6-arilo y -alquinil C2-6-heteroarilo; estando dichos alquilo C1-8, alquenilo C2-8 ó alquinilo C2-8 sin sustituir o sustituidos con uno o más sustituyentes seleccionados independientemente entre halógeno, -OR13, -NR10R13, ciano, nitro, -CO2R13, -CONR10R13, -NR10CONR10R13, -OCONR10R13, -SO2NR10R13 y -COR13; y estando cualquiera de dichos cicloalquilo, heterocicloalquilo, arilo o heteroarilo sin sustituir o sustituido con uno o más sustituyentes seleccionado independientemente entre alquilo C1-4, haloalquilo C1-4, halógeno, -OR13, -NR10R13, ciano, nitro, -CO2R13, -CONR10R13, -NR10CONR10R13, -OCONR10R13, -SO2NR10R13 y -COR13; cada R 13 se selecciona independientemente entre el grupo compuesto por hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, heterocicloalquilo, arilo, heteroarilo, -alquil C1-6-cicloalquilo C3-8, -alquil C1-6-heterocicloalquilo, -alquil C1-6-arilo y -alquil C1-6-heteroarilo; con la condición de que cuando X es O, Y es OH y Z, R1, R2, R3, R4, R5, R6, R7 y R8 son hidrógeno; W no sea hidrógeno, -CH3, -C2H5, -nC3H7, -nC4H9, -nC5H11, -nC6H13, -nC7H15, -(CH2)CH(CH3)2, -(CH2)2CH(CH3)2, -CH2CH=CH2, -CH2CH=CH(CH3), -(CH2)3CN, -(CH2)4CN, -(CH2)fenil
ARP020102090A 2001-06-07 2002-06-05 Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos AR036081A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29671201P 2001-06-07 2001-06-07
US33642801P 2001-10-29 2001-10-29

Publications (1)

Publication Number Publication Date
AR036081A1 true AR036081A1 (es) 2004-08-11

Family

ID=26969781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102090A AR036081A1 (es) 2001-06-07 2002-06-05 Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos

Country Status (16)

Country Link
US (1) US20040147739A1 (es)
EP (1) EP1401443A4 (es)
JP (1) JP2005501007A (es)
KR (1) KR20040006026A (es)
CN (1) CN1535151A (es)
AR (1) AR036081A1 (es)
BR (1) BR0210205A (es)
CA (1) CA2449770A1 (es)
CO (1) CO5540308A2 (es)
CZ (1) CZ20033326A3 (es)
HU (1) HUP0400149A2 (es)
IL (1) IL158992A0 (es)
MX (1) MXPA03011329A (es)
NO (1) NO20035428D0 (es)
PL (1) PL367217A1 (es)
WO (1) WO2002098424A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
ATE493408T1 (de) * 2002-11-01 2011-01-15 Abbott Lab Antiinfektiöse mittel
EP2361913A1 (en) * 2002-11-01 2011-08-31 Abbott Laboratories Anti-infective agents
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
WO2005019191A2 (en) * 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
UY28525A1 (es) 2003-09-22 2005-04-29 Boehringer Ingelheim Int Péptidos macrociclicos activos contra en virus de la hepatitis c
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CN103319464A (zh) 2004-02-20 2013-09-25 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
SG137868A1 (en) 2004-08-23 2007-12-28 Hoffmann La Roche Heterocyclic antiviral compounds
MX2007007264A (es) 2004-12-17 2007-08-14 Anadys Pharmaceuticals Inc Compuestos de piridazinona.
PL1831152T3 (pl) 2004-12-21 2009-03-31 Hoffmann La Roche Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT
CA2587793A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
JP2008540370A (ja) 2005-05-04 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス化合物
MX2007014117A (es) 2005-05-13 2008-02-05 Virochem Pharma Inc Compuestos y metodos para el tratamiento o prevencion de infecciones de flavivirus.
CN1319531C (zh) * 2005-06-08 2007-06-06 复旦大学 喹啉类生物碱在制备抗乙肝病毒药物中的用途
NZ567285A (en) 2005-11-03 2010-06-25 Hoffmann La Roche Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
KR20080094834A (ko) 2006-02-17 2008-10-24 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
CN102584649A (zh) * 2006-06-22 2012-07-18 安那迪斯药品股份有限公司 吡咯并[1,2-b]哒嗪酮化合物
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
MX2009003452A (es) 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.
NZ576780A (en) 2006-11-15 2011-12-22 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
CL2007003587A1 (es) 2006-12-12 2008-07-04 Anadys Pharmaceuticals Inc Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US7834009B2 (en) 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
WO2009152166A1 (en) 2008-06-10 2009-12-17 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
TW201026675A (en) 2008-10-09 2010-07-16 Anadys Pharmaceuticals Inc 5,6-dihydro-1H-pyridin-2-one compounds
EP2346329B1 (en) 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
EP2403844A1 (en) 2009-03-06 2012-01-11 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
MX2011011112A (es) 2009-04-25 2011-11-18 Hoffmann La Roche Compuestos antivirales heterociclicos.
KR20120024784A (ko) * 2009-05-20 2012-03-14 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
TW201103545A (en) 2009-06-24 2011-02-01 Hoffmann La Roche Heterocyclic antiviral compound
MX2012003170A (es) 2009-09-21 2012-04-11 Hoffmann La Roche Compuestos heterociclicos antivirales.
EP2493476A4 (en) 2009-10-28 2013-06-19 Anadys Pharmaceuticals Inc DEUTERATED 5,6-DIHYDRO-1H-PYRIDINE-2-ON COMPOUNDS
WO2011058084A1 (en) 2009-11-14 2011-05-19 F. Hoffmann-La Roche Ag Biomarkers for predicting rapid response to hcv treatment
BR112012012085A2 (pt) 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
WO2011068715A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
BR112012011393A2 (pt) 2009-12-02 2017-06-20 Hoffmann La Roche biomarcadores para a previsão da resposta sustentada ao tratamento de hcv
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP5883397B2 (ja) 2010-02-03 2016-03-15 ビオマリン プハルマセウトイカル インコーポレイテッド Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用
SI2533640T1 (sl) 2010-02-08 2017-02-28 Medivation Technologies, Inc. Postopki sinteze derivatov dihidropiridoftalazinona
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US20130157258A1 (en) 2010-06-15 2013-06-20 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
JP2013540158A (ja) 2010-10-21 2013-10-31 ビオマリン プハルマセウトイカル インコーポレイテッド 結晶性（８Ｓ，９Ｒ）−５−フルオロ−８−（４−フルオロフェニル）−９−（１−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−８，９−ジヒドロ−２Ｈ−ピリド［４，３，２−ｄｅ］フタラジン−３（７Ｈ）−オントシレート塩
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120321590A1 (en) 2011-04-06 2012-12-20 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
CN113773277B (zh) * 2021-09-18 2023-12-05 兰州大学 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法
CN115417892A (zh) * 2022-09-30 2022-12-02 福州大学 一种异噁唑取代的硼氮杂环化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829978A1 (de) * 1998-07-04 2000-01-05 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
WO2001085172A1 (en) * 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives

Also Published As

Publication number Publication date
WO2002098424B1 (en) 2004-02-26
WO2002098424A1 (en) 2002-12-12
CO5540308A2 (es) 2005-07-29
NO20035428D0 (no) 2003-12-05
BR0210205A (pt) 2004-09-14
KR20040006026A (ko) 2004-01-16
EP1401443A4 (en) 2005-10-26
IL158992A0 (en) 2004-05-12
HUP0400149A2 (hu) 2004-07-28
PL367217A1 (en) 2005-02-21
US20040147739A1 (en) 2004-07-29
JP2005501007A (ja) 2005-01-13
CA2449770A1 (en) 2002-12-12
CZ20033326A3 (cs) 2004-11-10
EP1401443A1 (en) 2004-03-31
MXPA03011329A (es) 2004-03-19
CN1535151A (zh) 2004-10-06

Similar Documents

Publication Publication Date Title
AR036081A1 (es) Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AR004972A1 (es) Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.
AR037851A1 (es) Antagonistas de neuroquinina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR088921A2 (es) PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
ECSP034431A (es) N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
BR9915895A (pt) Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase
AR073993A1 (es) Compuesto de pirazolilaminopiridina, composicion farmaceuticamente aceptable que lo comprende y su uso para preparar un medicamento util para tratar el cancer
BR9809652A (pt) Derivados de quinolina-4-carboxamida como antagonistas de receptor nk-2 e nk-3
AR044016A1 (es) Compuestos de 4-fenil piperidina y sus usos como moduladores de receptores opioides
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
RU2014143794A (ru) Производное конденсированного азола
DE602004027409D1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
AR015514A1 (es) Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载